Previous 10 | Next 10 |
2023-06-23 16:49:28 ET Summary BioVie will produce some lateral data from its phase 3 trial tomorrow. I was not overly impressed by its Alzheimer's program; the ascites program seemed more promising. The company is precariously low on cash. I will avoid for the time being. ...
2023-06-23 08:10:16 ET Drug therapies company BioVie ( NASDAQ: BIVI ) said on Friday that it is set to join the U.S. small-cap Russell 2000 and Russell 3000 indexes. The addition is effective after June 26 market open. BIVI shares were trading +3.42% pre-market. So...
CARSON CITY, Nev., June 23, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease,...
CARSON CITY, Nev., June 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease,...
--News Direct-- BioVie chief medical officer Dr Joseph Palumbo joins Natalie Stoberman from the Proactive newsroom to share the company's latest research and social impact on cognitive diseases to bring awareness to Alzheimer's & Brain Awareness Month. Palumbo says BioVie's latest...
BioVie Inc. (NASDAQ: BIVI) is the focus of IBN's latest stock spotlight. The company's shares have moved 5.36% on the day to $6.1. BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its prod...
2023-06-11 12:00:02 ET Driven by novel therapeutics from Biogen ( NASDAQ: BIIB )/ Eisai ( OTCPK:ESALF ) and Eli Lilly ( NYSE: LLY ), the Alzheimer’s disease market across eight major countries will reach $13.7B in 2030, the data analytics firm, GlobalData said las...
BioVie Inc. (NASDAQ: BIVI) is the focus of IBN's latest stock spotlight. The company's shares have moved -9.65% on the day to $5.67. BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its pr...
BioVie Inc. (NASDAQ: BIVI) is the focus of IBN's latest stock spotlight. The company's shares have moved -5.53% on the day to $6.24. BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its pr...
BioVie Inc. (NASDAQ: BIVI) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.86% on the day to $7.05. BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its pro...
News, Short Squeeze, Breakout and More Instantly...
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Ti...
SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who are naïve to carbidopa/levodopa Additional presentation at congress highlighted data from earlier Phase 2a trial of bezisterim in Parkinson...
ORLANDO, FL / ACCESSWIRE / June 21, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Mobilicom Ltd. (Nasdaq:MOB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 22, at 7 p.m. Eastern Time (ET). Bloomb...